Skip to main content
. Author manuscript; available in PMC: 2013 Sep 26.
Published in final edited form as: Clin Cancer Res. 2012 Jul 2;18(18):4931–4941. doi: 10.1158/1078-0432.CCR-12-0697

Figure 1. Impact of ATN-224 on anti-tumor efficacy of oHSV in vivo.

Figure 1

A) Tumor growth in subcutaneous (U251T3) tumor bearing mice treated with oHSV and ATN-224 or PBS (daily gavage). Thirteen days post initiation of gavage, mice were treated with rQnestin34.5 (1×105 pfu) or PBS by intra-tumoral injection (n=10). Data shown are the mean tumor volumes ± SEM, at the indicated time points. *: P < 0.05 versus rQnestin34.5 alone. B) Kaplan-Meier survival curve of mice with intracranial tumors (U87ΔEGFR) treated with PBS or ATN-224 (daily gavage), and treated with PBS or rQnestin34.5. *: P < 0.05 compared to mice treated with only rQnestin34.5. The arrows indicate the time of treatment with oHSV and the start of ATN-224 treatment.